Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
BioMarin Pharmaceutical
ClinicalTrials.gov Identifier:
NCT01114737
First received: April 27, 2010
Last updated: July 17, 2013
Last verified: July 2013

April 27, 2010
July 17, 2013
June 2010
March 2013   (final data collection date for primary outcome measure)
Evaluate the therapeutic effects of sapropterin dihydrochloride on the symptoms of ADHD and on global function compared to placebo, in subjects with a blood Phe level reduction after treatment. [ Time Frame: 13 weeks ] [ Designated as safety issue: No ]
ADHD change will be measured as a change in ADHD from baseline to week 13 using the Attention-Deficit Hyperactivity Disorder Rating Scale and Adult ADHD Self-Report Scale (ADHD RS/ASRS) measurement. Global function will be measured as a change in global function using the Clinical Global Impression-Improvement (CGI-I) scale rating compared from baseline to week 13.
Same as current
Complete list of historical versions of study NCT01114737 on ClinicalTrials.gov Archive Site
  • Evaluate the therapeutic effects of sapropterin dihydrochloride on the symptoms of anxiety and depression compared to placebo, in subjects with a blood Phe level reduction after treatment. [ Time Frame: 13 weeks ] [ Designated as safety issue: No ]
  • Evaluate the durability of any therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms and global function of subjects who have a blood Phe level reduction after treatment. [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
  • Determine if sapropterin dihydrochloride has a therapeutic effect on neuropsychiatric symptoms in PKU patients who do not have a blood Phe reduction after treatment. [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
  • Assess the safety of sapropterin dihydrochloride when administered as therapy to these patients. [ Time Frame: 26 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients
A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Subjects With Phenylketonuria

This double-blind, placebo-controlled, randomized study is designed to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with PKU.

Phenylketonuria (PKU) results from deficient phenylalanine hydroxylase (PAH) activity and leads to toxic phenylalanine (Phe) accumulation in patients with PKU causing mental retardation, microcephaly, delayed speech, seizures, psychiatric symptoms and behavioral abnormalities. Although for most PKU patients early initiation of dietary treatment prevents severe complications, discontinuation of dietary restrictions at an early age is associated with poor cognitive development and neuropsychiatric disorders are present even in early-treated and well controlled PKU patients.

This study, PKU-016, will be conducted in PKU patients to evaluate the therapeutic effects of sapropterin dihydrochloride on the symptoms of attention deficit hyperactivity disorder (ADHD), depression, and anxiety.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Phenylketonuria
  • Drug: Sapropterin dihydrochloride
    A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
    Other Names:
    • Kuvan
    • Phenoptin
    • BH4
    • 6R BH4
  • Drug: Placebo
    Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
  • Experimental: Sapropterin dihydrochloride
    Intervention: Drug: Sapropterin dihydrochloride
  • Placebo Comparator: Tablet without active ingredient
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
March 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • ≥ 8 years of age
  • Confirmed diagnosis of PKU
  • Willing to continue current diet (typical diet for the 3 months prior to study entry) unchanged while participating in the study
  • Willing and able to provide written, signed informed consent or in the case of subjects under the age of 18, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures
  • Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study and for at least 30 days following the last dose of sapropterin dihydrochloride
  • Females of childbearing potential must have a negative pregnancy test at screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to screening, or have had total hysterectomy.
  • Willing and able to comply with all study procedure

Exclusion Criteria:

  • Has known hypersensitivity to sapropterin dihydrochloride or its excipients
  • Subject breastfeeding at screening or planning to become pregnant (subject or partner) at any time during the study
  • Use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to the completion of all scheduled study assessments
  • Received sapropterin dihydrochloride within 16 weeks of randomization
  • Have initiated or adjusted medication for treatment of ADHD, depression, or anxiety ≤ 8 weeks prior to randomization
  • Taking medication known to inhibit folate synthesis (eg, methotrexate)
  • Any condition requiring treatment with levodopa or any PDE-5 inhibitor
  • Concurrent disease or condition that would interfere with study participation, compliance or safety as determined by the Investigator
  • Any condition that, in the view of the Investigator, places the subject at high risk of poor treatment compliance or of not completing the study
Both
8 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT01114737
PKU-016, PKU Ascend
Yes
BioMarin Pharmaceutical
BioMarin Pharmaceutical
Not Provided
Study Director: Suyash Prasad, MD BioMarin Pharmaceutical
BioMarin Pharmaceutical
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP